1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. BIOCON LTD.
Biocon Ltd.
NSE: BIOCON | BSE: 532523

Biocon Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutBiocon Ltd. is a global biopharmaceutical company based in India, specializing in the development and manufacturing of affordable therapies for chronic diseases such as diabetes, oncology, and immunology. The company operates through four key busines... Read More
Clinical TrialsPatent Approvals
Ask AI about Biocon
351.80-0.10(-0.03%)

52W Low on Oct 23, 2026

2.1M
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Biocon is on 04 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
41.4 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

14

S

12

W

8

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

14Positive9Negative

Pass in checklist60.9%

045
55
100

PE Valuation Check

Right Now
Overvalued
-30%
1 Year Forward
Undervalued
54.5%
INSIGHTBiocon is overvalued at current PE, but undervalued on future earnings estimates

Biocon Stock Price Analysis

Day Price Range

-0.0% 1 Day return
351.8 (LTP)
348.7355.5
LowHigh

Week Price Range

8.8% 1 Week return
351.8 (LTP)
321.3357.3
LowHigh

Month Price Range

-6.7% 1 Month return
351.8 (LTP)
318.4381.2
LowHigh

52 Week Price Range

-6.6% 1 Year return
351.8 (LTP)
318.4447.2
LowHigh
View full Price History/Seasonality

Biocon Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Biocon's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
2.8
AVG. ESTIMATE
6.6
LOW ESTIMATE
5.2
HIGH ESTIMATE
8.1
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 133.3% in FY27

Consensus Recommendation

18 ANALYST Recommendations
BUY

The consensus recommendation from 18 analysts for Biocon is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Biocon Technical Analysis

Biocon EMA & SMA

Neutral0
4 bullish, 4 bearish
Bullish4
Bearish4
5 Day345.9
10 Day344.3
12 Day345.0
20 Day350.4
26 Day355.1
50 Day370.7
100 Day384.6
200 Day387.3

Biocon Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202647.0%
Week46.8%
Month53.7%

Biocon Active Candlesticks

Long Legged Doji Uptrend Rickshaw Man Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Biocon Resistance and Support

352.00
Pivot
First Resistance355.3
Second Resistance358.8
Third Resistance362.1
First Support348.5
Second Support345.2
Third Support341.7
Day RSI46.8
Day MACD-10.1
Day MFI54.2
Day MACD Signal Line-12.8

Biocon Beta

1 Month0.9
1 Year0.7
3 Month0.8
3 Year1.0

Biocon Price Change Analysis

↓-6.7%
Over 1 Month
LowHigh
318.4381.2
↓-17.3%
Over 3 Months
LowHigh
318.4442.5
↓-2.9%
Over 6 Months
LowHigh
318.4447.2
↓-6.6%
Over 1 Year
LowHigh
318.4447.2
All Technicals →

Biocon Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Kiran Mazumdar-ShawPromoter484,581,97029.7 %
Serum Institute Life Sciences Private LimitedPublic55,448,7653.4 %
Sbi Esg Exclusionary Strategy FundDii149,620,8309.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Biocon Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
ACTIV PINE LLPBlockSell09 Sep 20263857,403,166BSE
ACTIV PINE LLPBlockSell09 Sep 20263851,423,998BSE
ACTIV PINE LLPBlockSell09 Sep 20263851,277,000BSE
ACTIV PINE LLPBlockSell09 Sep 20263851,277,000BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
ACTIV PINE LLPBlockSell09 Sep 2026385650,002BSE
All deals
All insider trades

Biocon Corporate Actions

Biocon Dividend history and yield

Biocon dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Biocon dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
103 Jul 2026
0.5FINAL03 Jul 2026Equity Share
204 Jul 2025
0.5FINAL04 Jul 2025Equity Share
305 Jul 2024
0.5FINAL05 Jul 2024Equity Share
407 Jul 2023
1.5FINAL07 Jul 2023Equity Share
530 Jun 2022
0.5FINAL01 Jul 2022Equity Share

Biocon Bonus shares

Biocon bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
112 Jun 2019
1:113 Jun 2019
215 Jun 2017
2:117 Jun 2017
311 Sep 2008
1:112 Sep 2008

Biocon Board Meetings

Biocon past and upcoming board meetings.

#Ex-Date
PurposeNotes
104 Nov 2026
Quarterly Results-
205 Aug 2026
Quarterly Results-
307 May 2026
Audited Results & Final Dividend-
412 Feb 2026
Quarterly Results-
511 Nov 2025
Quarterly Results-
All Corporate Actions

Biocon Research Reports

Biocon research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
120 Sep 2026Axis Direct424395Buy7.34%-10.94%pdf
205 Aug 2026Motilal Oswal
Target
520436.6Buy19.1%-19.42%pdf
315 Feb 2026Axis Direct435380.35Buy14.37%-7.51%pdf
412 Feb 2026Motilal Oswal450377.95Buy19.06%-6.92%pdf
501 Jan 2026Geojit BNP Paribas
Reco
Target
439392.95Accumulate11.72%-10.47%pdf
All Reports of Biocon

Biocon Corporate Filings

Biocon BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
PDF
26 Oct 2026
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call for Analysts and Investors
PDF
26 Oct 2026
Biocon Ltd - 532523 - Board Meeting Intimation for To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2026
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve To approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026
PDF
26 Oct 2026
Biocon Ltd - 532523 - Company Statement
Company Statement
PDF
14 Oct 2026
Biocon Ltd - 532523 - Company Statement
Company Statement
PDF
VIEW ALL

Biocon DocumentsAsk MarketMind AI

Biocon Earnings Call

Biocon earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
11 Aug 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
06 Aug 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
14 May 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
17 Feb 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
18 Nov 2025Biocon Ltd - 532523 - Transcript Of Earnings Call Q2 FY26Link
view all

Biocon Annual Reports

Biocon financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Biocon Credit Ratings

Biocon credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
15 Dec 2025icra ratingsBiocon LimitedUpdate on material eventLink
15 Dec 2025crisil ratingsBiocon LimitedBiocon Limited:Ratings reaffirmed at 'Crisil AA+ / Stable / Crisil A1+ 'Link
08 Dec 2025india ratingsIndia Ratings Assigns Biocon’s Additional Bank Loan Facilities ‘IND AA+’/Stable & Proposed CP ‘IND A1+; Affirms Existing; Withdraws NCDsLink
29 Oct 2025icra ratingsBiocon LimitedRatings reaffirmedLink
16 Jun 2025crisil ratingsBiocon LimitedBiocon Limited:Ratings reaffirmed at 'Crisil AA+/Stable/Crisil A1+'Link

Biocon Investor Presentations

Biocon investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
06 Aug 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
01 Jun 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
08 May 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
25 Feb 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Feb 2026Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Biocon - Company Profile

Biocon Management Structure

Biocon management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
RAJESH UMAKANT SHANOYCompany Secretary,Compliance Officer-Mar 26
Mr. Shreehas TambeManaging Director,Chief Executive Officer-Mar 26
Mr. Kedar UpadhyeChief Financial Officer-Mar 26
Mrs. Rhonda DuffyChief operations Officer-Mar 26
Mr. Matthew ErickChief Commercial Officer(Advanced Markets)-Mar 26
Mr. Susheel UmeshChief Commercial Officer(Emerging Markets),Head(Global)-Mar 26
Dr Anuj GoelChief Development Officer-Mar 26
Mr. Naveen NarayananChief Human Resources Officer-Mar 26
Mr. Mandar GhatnekarChief Technology Officer-Mar 26

Biocon Board of Directors

Biocon Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Kiran Mazumdar ShawChairperson549.6Mar 26
Naina Lal KidwaiLead Independent Director102.1Mar 26
NICHOLAS ROBERT HAGGARIndependent Non Exe. Director80.5Mar 26
Rekha Mehrotra MenonIndependent Non Exe. Director79.9Mar 26
Ravi MazumdarNon-Exec & Non-Independent Dir79Mar 26
Atul DhawanIndependent Non Exe. Director74Mar 26
Eric Vivek MazumdarNon-Exec & Non-Independent Dir66.8Mar 26
Shreehas Pradeep TambeManaging Director & CEO-Mar 26
RAJESH UMAKANT SHANOYCompany Sec. & Compli. Officer-Mar 26

Biocon Brands

Brands owned by Biocon

LOGOBRAND NAME
Actiblok IPR
Alzumab
Celrim
Alzumab-L
LOGOBRAND NAME
Calpsor Ointment
Ixza
Thinla
Thinwes
LOGOBRAND NAME
Insugen 100 50/50 / 30/70
Metadoze-IPR
Insugen Refil R
Insugen Refil N
LOGOBRAND NAME
Alizap
Picon Lotion
Picon Cream
Tbis Lotion
Website: www.biocon.com

About the company - Business Profile

Biocon Ltd. is a global biopharmaceutical company based in India, specializing in the development and manufacturing of affordable therapies for chronic diseases such as diabetes, oncology, and immunology. The company operates through four key business segments: Generics, Biosimilars (Biocon Biologics), Research Services (Syngene), and Novel Biologics. Biocon has established a presence in over 120 countries, leveraging a vertically integrated model to manage the entire value chain from discovery to commercialization.

Key Points

Key Facts

  • Founded: 1978.
  • Headquarters: Bengaluru, India.
  • Stock Listing: Listed on BSE and NSE.
  • Total Income (FY25): ₹164,699 million ($1.95 billion), reflecting a 5% year-on-year growth.
  • Key Subsidiaries: Biocon Biologics (Biosimilars) and Syngene International Ltd. (CRDMO).

Operations and Resources

  • Manufacturing: Operates 11 manufacturing locations with over 215 cGMP (Current Good Manufacturing Practice) approvals globally.
  • Integration: The company utilizes a vertically integrated model, especially in its biosimilars and generics segments, to control costs and ensure quality.
  • Research & Development: Gross R&D investment for FY25 stood at ₹8,585 million ($102 million). The company holds over 1,500 patents.

Ownership and Market Significance

  • Structure: Biocon Ltd. holds a 52.4% stake in Syngene International and a significant majority in Biocon Biologics. It also holds a 10.1% stake in Bicara Therapeutics, which is listed on NASDAQ.
  • Strategic Importance: Biocon is a leader in interchangeable insulins and generic GLP-1 peptides. It serves 14 of the top 20 global pharmaceutical companies through its research services.

Revenue Breakdown by Business Segment (FY25)

  • Biosimilars: ₹90,174 million (58% of revenue contribution).
  • Research Services (Syngene): ₹36,424 million (23% of revenue contribution).
  • Generics: ₹30,175 million (19% of revenue contribution).

Key Products and Technology

  • Biosimilars: Portfolio includes Yesintek (ustekinumab), Ogivri (trastuzumab), and Abevmy (bevacizumab). In FY26, the company gained market traction with Yesintek in North America.
  • Insulins: Notable products include Insugen (recombinant human insulin) and Basalog (insulin glargine). Biocon launched the first interchangeable bAspart in the U.S. during Q2 FY26.
  • Generics: Focus on APIs (Active Pharmaceutical Ingredients), GLP-1s, and finished dosages (OSDs and injectables).

Strategic Initiatives and Future Outlook

  • Corporate Consolidation: A proposed merger of Biocon Limited and Biocon Biologics aims to simplify the group structure, remove holding company discounts, and consolidate resources across biosimilars and generics.
  • Debt Reduction: Reducing acquisition debt remains a priority; the company paid down $250 million of acquisition-related debt in FY24.
  • Growth Areas: Transitioning toward sustainable growth through high-growth segments like oncology (addressing a $75+ billion opportunity) and metabolic care.

Human Capital

  • Workforce: The Group maintains a significant scientific talent pool, with Syngene alone employing over 5,500 scientists.
  • Diversity: Women representation in the workforce is 27% at Biocon Limited and 22% at Biocon Biologics.
  • Training: Employees completed over 7.06 million training hours in the most recent fiscal period.

Sustainability and Innovation

  • Environmental: Achieved a reduction of 148,353 tCO2e in total GHG emissions (Scope 1 & 2) in FY25. Renewable power usage reached 80% for India operations.
  • Social: Benefited 21.2 million patients through generics and biosimilars and spent ₹324.6 million on CSR initiatives.

References

  1. Annual Report May 2024
  2. Annual Report May 2025
  3. Investor Presentation Nov 2025
  4. Investor Presentation Dec 2025
  5. Investor Presentation Dec 2025
  6. Investor Presentation Feb 2026
  7. Investor Presentation Feb 2026

Biocon FAQ

Biocon today is trading in the red, down by 0.03% at ₹351.8.
Biocon is currently trading down 0.03% on an intraday basis. In the past week the stock rose 8.75%. Stock has been down 17.29% in the past quarter and fell 6.59% in the past year. You can view this in the share price history/seasonality section.
Biocon is listed on NSE with the ticker BIOCON and on BSE as 532523. It's currently trading on NSE at a share price of ₹351.8 and on BSE with a share price of ₹352.
The market cap of Biocon is ₹57,332.64 Cr. as of Oct 30, 2026.
Biocon announced a FINAL dividend of 10% which equals ₹0.5 in Jul 03, 2026.The last three ex-dates for Biocon were Jul 04, 2025, Jul 05, 2024 and Jul 07, 2023. To view the full dividend history of Biocon click here.
Biocon has never issued stock splits, but it has issued 3 bonus shares since its BSE/NSE listing. The latest announcement for Biocon bonus shares was on Jun 12, 2019 at a ratio of 1:1.
Biocon reported ₹4,390.5 Cr. in revenue, ₹141.1 Cr. in net profit, and ₹888.2 Cr. in EBITD as of Aug 05, 2026 for Q1 FY26-27.
According to the predictions of 19 analysts, the share price prediction for Biocon is ₹440.16 with an upside of 25%.
The PE ratio of Biocon is 115.75 as of Oct 30, 2026.
The PB ratio of Biocon is 1.68 as of Oct 30, 2026.
You can view the latest analyst reports on the Biocon reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×